Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03586869 · ClinicalTrials.gov registry record · Phase 1
QUILT-3.080: NANT Pancreatic Cancer Vaccine
A Phase 1 study, sponsored by ImmunityBio.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03586869 is a Phase 1 study that was terminated before completion, run by ImmunityBio. The registered enrollment target is 3 participants.
The verdict
NCT03586869, a Phase 1 study, was terminated before completion, sponsored by ImmunityBio.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous Standard of Care (SoC) chemotherapy.
Interventions
- DRUG Aldoxorubicin HCl
- BIOLOGICAL ALT-803
- BIOLOGICAL ETBX-011
- BIOLOGICAL ETBX-021
- BIOLOGICAL ETBX-051
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-07-17 |
| Est. Completion | 2019-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03586869
The ClinicalTrials.gov registry entry for NCT03586869 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Aldoxorubicin HCl is the first listed.
NCT03586869 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03586869 about?
NCT03586869 is a clinical study titled "QUILT-3.080: NANT Pancreatic Cancer Vaccine". This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous Standard of Care (SoC) chemotherapy.
What is the current status of trial NCT03586869?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2018-07-17. Estimated completion is 2019-08-01.
What interventions are being tested in trial NCT03586869?
The interventions under investigation include: Aldoxorubicin HCl (DRUG), ALT-803 (BIOLOGICAL), ETBX-011 (BIOLOGICAL), ETBX-021 (BIOLOGICAL), ETBX-051 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03586869?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.